Sie sind nicht angemeldet! Dieses Tagebuch ist öffentlich einsehbar und wird demnächst zurückgesetzt.
 | |||||||
| |||||||
| © tratabu.de
© tratabu.de
|
Dividendenzahlungen |
|||
| Titel | Ex-Datum | Zahldatum | Bruttobetrag |
Carl Zeiss Meditec AG |
27.03.25 |
31.03.25 |
0.6000 € |
Carl Zeiss Meditec AG |
22.03.24 |
26.03.24 |
1.1000 € |
Carl Zeiss Meditec AG |
21.03.24 |
1.1000 € |
|
Carl Zeiss Meditec AG |
24.03.23 |
1.1000 € |
|
Carl Zeiss Meditec AG |
23.03.23 |
27.03.23 |
1.1000 € |
Carl Zeiss Meditec AG |
01.04.22 |
0.9000 € |
|
Carl Zeiss Meditec AG |
31.03.22 |
04.04.22 |
0.9000 € |
Carl Zeiss Meditec AG |
28.05.21 |
01.06.21 |
0.5000 € |
Carl Zeiss Meditec AG |
07.08.20 |
11.08.20 |
0.6500 € |
Carl Zeiss Meditec AG |
25.03.20 |
0.6500 € |
|
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 20.07.25 08:14:35 | Carl Zeiss Meditec (ETR:AFX) shareholders have endured a 62% loss from investing in the stock three years ago |  |
| If you love investing in stocks you're bound to buy some losers. Long term Carl Zeiss Meditec AG (ETR:AFX) shareholders know that all too well, since the share price is down considerably over three years. Sadly for them, the share price is down 63% in that time. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During the three years that the share price fell, Carl Zeiss Meditec's earnings per share (EPS) dropped by 16% each year. This reduction in EPS is slower than the 28% annual reduction in the share price. So it seems the market was too confident about the business, in the past. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).XTRA:AFX Earnings Per Share Growth July 20th 2025 Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. A Different Perspective While the broader market gained around 23% in the last year, Carl Zeiss Meditec shareholders lost 16% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Carl Zeiss Meditec better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Carl Zeiss Meditec , and understanding them should be part of your investment process. For those who like to find winning investments this freelist of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 17.07.25 02:00:00 | ZEISS Group Appoints Martin Fischer as President and CEO of ZEISS Greater China |  |
| SHANGHAI, July 17, 2025 /PRNewswire/ -- ZEISS Group recently announced that Martin Fischer will officially take on the role of President and CEO of ZEISS Greater China, effective from October 1, 2025, reporting directly to Andreas Pecher, President and CEO of the ZEISS Group. Martin Fischer succeeds Maximilian Foerst, who joined the Executive Board of the ZEISS Group as the President and CEO of Carl Zeiss Meditec AG on June 1, 2025. ZEISS Greater China manages all business activities in China's mainland, Hong Kong SAR, and Taiwan Region.ZEISS Group Appoints Martin Fischer as President and CEO of ZEISS Greater China "ZEISS's commitment to Greater China remains strong. China is ZEISS's largest market and is an important cornerstone in its global footprint. I am very pleased that Martin Fischer has agreed to take on this important position," says Andreas Pecher. "Martin is a very experienced leader, who is already quite familiar with ZEISS and our customers. This will ensure a smooth transition as we continue our Greater China strategy that started under Maximilian Foerst's leadership." Martin Fischer joined ZEISS in 2006 and has held positions at various business segments including Semiconductor Manufacturing Technology (SMT), Industrial Quality Solutions (IQS), and Research Microscopy Solutions (RMS). Since 2022, he has been Global Head of Sales, Service & Marketing for RMS. In this position, he has expanded the commercial organization to include marketing and customer experience. He also set up and led various strategically important programs. These have enabled the RMS team to successfully sell agnostic software and enter the future growth markets of biotech & pharma as well as electronics/semiconductors. In addition, he has made important contributions to regional growth projects in the US and APAC, and to the strategic programs for the ZEISS Group. "I am very honored to be appointed as President and CEO of ZEISS Greater China. Maximilian successfully led all the business segments in the region for the past 16 years, laying a solid foundation for future development," said Martin Fischer. "I am excited to lead the Greater China team, which consists of a strong and efficient management team, along with thousands of dedicated and passionate employees. The strategic development of ZEISS Greater China is at the forefront of the Group, and I look forward to achieving more progress in innovation, localization, and all business segments in the future." About ZEISS Group ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the fiscal year 2023/24, the ZEISS Group generated annual revenue totaling nearly 11 billion euros in its four segments: Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (as of 30 September 2024). Currently, 15 percent of revenue is invested in science and R&D. Story Continues For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars. With a portfolio aligned with future growth areas like digitalization, healthcare and smart production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS's technology and market leadership. Today, around 46,500 employees work at the ZEISS Group globally in around 50 countries. The company is headquartered in Oberkochen (Germany). The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG. Further information available at www.zeiss.com About ZEISS in Greater China ZEISS' history in Greater China dates to 1957. ZEISS is now represented in the Greater China market with all segments including Semiconductor Manufacturing Technology, Industry Quality & Research, Medical Technology, and Consumer Markets. Since 2021, China has become ZEISS's largest single market in the world, and one of the most innovative and fastest-growing markets. In the fiscal year 2023/24, ZEISS in Greater China generated annual revenue totaling 15.1 billion RMB, with a 12% increase compared to the prior year. Over 7,000 employees throughout the country with more than 60 sites of manufacturing factories, sales & service offices and R&D centers strongly support our customers in the region, and guarantee every related business internationally. The headquarters of ZEISS Greater China is located in Shanghai Pilot Free Trade Zone. It is home to a wide range of activities: China Sales & Service headquarters, competence and training centers, manufacturing facility for the ZEISS Industrial Metrology business group and Shanghai Innovation and R&D Center, ZEISS Group's first corporate innovation and R&D center outside of Germany. ZEISS regional headquarters and the Innovation and R&D Center in Shanghai, together with the Suzhou R&D and Manufacturing Site and Guangzhou Knowledge Manufacturing Base are creating a closed-loop industrial chain that includes medical devices, high-end manufacturing and R&D equipment, and optical lenses. ZEISS is committed to supporting domestic R&D and works closely with Chinese partners to ensure the high-quality and sustainable development of China's cutting-edge industries. Further information available at www.zeiss.com.cnCision View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/zeiss-group-appoints-martin-fischer-as-president-and-ceo-of-zeiss-greater-china-302507386.html SOURCE ZEISS Group View Comments |
||
| 17.04.25 13:00:00 | ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone | |
| Showcasing at ASCRS 2025: More than 2 million cases planned with ZEISS VERACITY Surgery Planner: Growing use of one of the leading digital planning solutions for cataract surgery in the U.S. is a testament to the increased adoption of the ZEISS Cataract Workflow digital solutions by surgeons. ZEISS MEL 90 broadens refractive treatment portfolio: U.S. availability of both the ZEISS MEL 90 and ZEISS VISUMAX 800 extends the company's LVC market leadership with treatments for myopia, hyperopia, and mixed astigmatism. Enhanced cataract portfolio with DORC and FCI: Showcasing cataract solutions from DORC and FCI for the first time in the ZEISS booth #1501. JENA, Germany and DUBLIN, Calif., April 17, 2025 /PRNewswire/ -- ZEISS Medical Technology will celebrate the rapid adoption of digital cataract solutions and showcase newly available refractive treatment technology at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25 – 27 in Los Angeles, CA. ZEISS marks a major milestone in the U.S. with more than 2 million digitally planned cases using the ZEISS VERACITY Surgery Planner,1 one of the leading digital planning solutions for cataract surgery, which serves as a testament to the growing number of surgeons discovering the benefits of digital workflows in the delivery of patient care and treatments.ZEISS VERACITY Surgery Planner "The digital era continues to grow at a rapid pace. Ophthalmologists are increasingly realizing the significant benefits of using digital workflows as the backbone of their medical practices," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "ZEISS has much to celebrate at ASCRS this year, including our continued U.S. leadership in digital innovation and ongoing commitment to improving patient care across both the cataract and refractive markets." Additionally, the ZEISS Refractive Workflow will showcase for the first time both the VISUMAX® 800 with SMILE® pro from ZEISS and the MEL® 90 from ZEISS, helping to further broaden a surgeon's refractive business with improved patient attraction and positive clinical outcomes. Lastly, for the first time, DORC and FCI, both ZEISS companies, are set to present their portfolio of cataract surgical solutions in the ZEISS booth, showcasing the extended benefits of ZEISS's surgical portfolio. More than 2 million cases planned using ZEISS VERACITY Surgery Planner reflects growing digital adoption by U.S. cataract surgeons ZEISS VERACITY Surgery Planner is one of the top digital planning solutions for cataract surgery in the U.S. today with thousands of users logging in to plan their surgical cases, pulling data from most modern EMRs, 19 different diagnostic devices, and optional data sources like patient questionnaires, in order to make data-driven informed decisions designed to drive better patient outcomes in clinics and ORs. Story Continues At ASCRS, ZEISS will celebrate the significant milestone of its cloud-based ZEISS VERACITY Surgery Planner, with more than 2 million cases planned. A recent study showed that with the ZEISS Cataract Workflow powered by ZEISS VERACITY Surgery Planner, surgeons and staff can save up to 60% of their time per eye compared to traditional paper planning.2 Kerry Solomon, MD, from Carolina Eye Care Physicians, one of the creators of VERACITY prior to its acquisition by ZEISS in 2017, says, "Today we're up to 2 million plans, unbelievable! When we first started developing this solution, I absolutely envisioned we'd get to where we are today, and I'm thrilled with where we're at!" In addition to proven efficiency gains, new research abstracts presented at this year's ASCRS showcase excellent refractive accuracy and clinical outcomes when adopting the ZEISS Cataract Workflow: Steven C. Schallhorn, MD, ABO, will present a clear benefit of reducing postoperative astigmatism by implanting toric IOLs in patients with lower preoperative corneal astigmatism, leveraging cataract outcomes obtained from VERACITY Surgery Planner's database of 50,850 eyes with preoperative corneal astigmatism between 0.75D and 1.50D. Luke Rebenitsch, MD, ABO, will present a comparison of refractive outcomes in a large cohort of 49,057 eyes undergoing cataract surgery with toric IOL implantation where the use of the ZEISS CALLISTO eye system resulted in significant improvements in terms of post-op refractive outcomes compared to a manual marking approach. Kamran M. Riaz, MD, ABO, will present an analysis of the refractive accuracy of two biometers in a cohort of 222 eyes with prior laser vision correction and implantation of toric multifocal IOLs, highlighting the significantly better performance of total keratometry with the IOLMaster 700. Enhanced refractive treatment portfolio enables a higher standard of refractive patient care with both the ZEISS VISUMAX 800 and ZEISS MEL 90 ZEISS continues to set high standards in refractive patient care in the U.S. with the availability of both the ZEISS VISUMAX 800 and ZEISS MEL 90. For the first time, the ZEISS MEL 90 will be showcased in the U.S. at ASCRS, extending ZEISS's LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism. "The FDA approval of the ZEISS MEL 90 excimer laser is a game changer for refractive surgery in the U.S. I am particularly impressed by the system's ability to simplify treatment planning while delivering highly predictable and tissue-conserving results. This approval marks an exciting chapter for surgeons and patients alike," says Dr. John Doane, Refractive Surgeon, Discover Vision Centers, Kansas City, MO (USA). The MEL® 90 from ZEISS aims to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX® 800 with SMILE® pro from ZEISS to help further broaden a surgeon's refractive business with improved patient attraction and positive clinical outcomes. The ZEISS VISUMAX 800 with ZEISS SMILE pro software enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.3 The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise. Showcasing the benefits of ZEISS's surgical portfolio to help meet the evolving clinical challenges of surgeons in the U.S. ZEISS will showcase for the first time together in the ZEISS booth key solutions from DORC and FCI. This will feature the DORC EVA NEXUS™ surgical system for cataract and phaco-vitrectomy surgeries. It will also include the DORC VisionBlue® anterior stain, a trusted choice in more than 10 million cataract surgeries since its introduction. As the only FDA-approved trypan blue stain for anterior applications, it is also authorized for staining Descemet's membrane and trabecular meshwork. Additionally, the ZEISS booth will feature the FDA-approved Eyejet® 20C from Morcher®, built on the gold standard preloaded Eyejet® system and designed to prevent toric IOLs rotation, providing maximum toric benefits. ZEISS will showcase its latest offerings and new innovations at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25-27, 2025, in Los Angeles, CA, at booth #1501. For more information, visit www.zeiss.com/med. 1 Data on file. 2 Gujral, Tarika, and John Hovanesian. "Cataract Surgical Planning Using Online Software vs Traditional Methods." Clinical Ophthalmology (Auckland, N.Z.), U.S. National Library of Medicine, 28 July 2021. 3 Data on file, myopia with optical zone 6.5 mm. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investors Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220 116 Mail: investors.meditec@zeiss.com Contact for the press Frank Smith Head of Global Communications Ophthalmology Carl Zeiss Meditec Inc. Phone: +49 3641 220 331 Mail: press.med@zeiss.com www.zeiss.com/newsroom Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: www.zeiss.com/medZEISS MEL 90 Excimer LaserZEISS SOURCE Carl Zeiss Meditec AG View Comments |
||
| 09.04.25 11:11:00 | ZEISS receives FDA clearance for INTRABEAM 700 | |
| With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy. JENA, Germany, April 9, 2025 /PRNewswire/ -- As a leading provider of medical solutions in the field of neurosurgery, ZEISS Medical Technology is also dedicated to shaping modern oncology. The company recently received 510(k) clearance from the US Food and Drug Administration (FDA) for INTRABEAM® 700 – a leading-edge platform that provides robotic-assisted precision to support intraoperative radiation therapy (IORT). With its modern digital-first architecture, ZEISS INTRABEAM 700 creates SMART workflow efficiency and provides seamless connectivity, offering real added value for neurooncology and breast cancer therapy.ZEISS INTRABEAM 700 "Based on our established INTRABEAM platform, the newly developed ZEISS INTRABEAM 700 marks the next major step on our path to shaping the oncology workflows of tomorrow," says Dr. Christian Schwedes, Head of the Neuro- and Spine Surgery Business Sector at ZEISS Medical Technology. "It is especially designed for a precise, structured and risk-adapted treatment of brain tumors. From smart robotic positioning of the system, a more efficient workflow before and during the application, to bringing the system into the 21st century when it comes to digitalization and connectivity, the ZEISS INTRABEAM 700 will support the efficient and seamless collaboration between neurosurgery and oncological therapy." Robotic-assisted Precision In oncological treatments, it must be ensured that the target area is optimally resected, and that healthy tissue is spared as much as possible. Especially during contact irradiation, it is important that the target focus always remains the same throughout the entire treatment, without interruptions or unintended movements. The cutting-edge maneuverability of the brand-new robotic ZEISS INTRABEAM SMART Stand meets these clinical requirements and offers excellent positioning control at every stage of the treatment. ZEISS INTRABEAM SMART Stand supports the precise positioning of the applicator by allowing it to approach the cavity fast, but also to slow down the speed of movement when navigating the applicator within the cavity. Once the applicator is in place, the active damping and the stand dynamics reduce residual vibrations to a minimum. "The new incarnation of the INTRABEAM 700 really gives you more range of motion in the delivery of the applicator to the cavity. It gives you precision in how movements can be made inside of the resection cavity by the applicator," says Christopher Cifarelli, MD Neurosurgeon, West Virginia University, USA. Story Continues SMART Workflow Efficiency To achieve the best patient outcomes, healthcare professionals would like to focus solely on the treatment. ZEISS INTRABEAM 700 offers Smart Workflow Efficiency based on a digital-first architecture: The new sterile ZEISS INTRABEAM SMART Spherical Applicators come with digital-assisted applicator management and the related ZEISS INTRABEAM Spherical Sizer Set also eliminates the need for sterilization. The convenient and smart draping and balancing functions support clinical workflow efficiency further. With a single tap, all functions can be controlled with a modern and intuitive graphical user interface (GUI), familiar from other ZEISS devices. Furthermore, the completely redesigned Radiance™ treatment planning simulation software enables oncologists to assess and simulate all relevant intraoperative radiation dosage parameters based on individual patient data prior to treatment in a simpler and faster workflow, reducing unexpected treatment disruptions during surgery. This is key to successful surgical oncology procedures, resulting in optimal patient outcomes. Seamless Connectivity As part of the digitalization megatrend, connectivity is also becoming increasingly important in surgical oncology workflows worldwide. ZEISS INTRABEAM 700 can be integrated seamlessly into the surgical infrastructure and the hospital information system. Direct access to leading digital solutions from ZEISS enables faster routine workflows and simplified data management. The platform also provides integrated applicator recognition and confirmation through embedded Radio Frequency Identification (RFID) technology. For progress in medical technology The latest generation of the INTRABEAM platform highlights ZEISS' innovative strength and is an example of how the company is driving medical innovation in cancer therapy: INTRABEAM from ZEISS is currently already used in multiple large clinical studies to research intraoperative radiotherapy in brain tumors, and clinical data has already been published. In addition, work on new clinical and patient-related data in the field of breast cancer is ongoing.* ZEISS will present its latest solution for intraoperative radiotherapy from April 25 to 28, 2025, at the American Association of Neurological Surgeons Annual Scientific Meeting (AANS) in Boston, booth no. 625. * INTRAMET – phase 2 study – Brain Metastases – publication expected in 2026; INTRAGO II – phase 3 study – Glioblastoma – completed in 2024 (publication expected for 2026); TARGIT-E – phase 3 study Breast cancer in elderly patients – publication expected in 2025; TARGIT-US – phase 4 study Breast cancer – publication expected in 2027. Contact for investors and the press Sebastian Frericks Head of Group Finance and Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220 116 Mail: investors.med@zeiss.com www.zeiss.com/newsroom Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: www.zeiss.com/med Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.ZEISS Logo (PRNewsfoto/Carl Zeiss Meditec AG)Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zeiss-receives-fda-clearance-for-intrabeam-700-302424427.html SOURCE Carl Zeiss Meditec AG View Comments |
||
| 08.04.25 13:36:04 | Carl Zeiss Meditec AG's (ETR:AFX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? | |
| Carl Zeiss Meditec (ETR:AFX) has had a rough month with its share price down 17%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Carl Zeiss Meditec's ROE in this article. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. How To Calculate Return On Equity? Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Carl Zeiss Meditec is: 7.7% = €158m ÷ €2.1b (Based on the trailing twelve months to December 2024). The 'return' is the yearly profit. One way to conceptualize this is that for each €1 of shareholders' capital it has, the company made €0.08 in profit. Check out our latest analysis for Carl Zeiss Meditec What Has ROE Got To Do With Earnings Growth? Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics. Carl Zeiss Meditec's Earnings Growth And 7.7% ROE When you first look at it, Carl Zeiss Meditec's ROE doesn't look that attractive. Yet, a closer study shows that the company's ROE is similar to the industry average of 9.5%. Having said that, Carl Zeiss Meditec has shown a modest net income growth of 8.9% over the past five years. Considering the moderately low ROE, it is quite possible that there might be some other aspects that are positively influencing the company's earnings growth. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio. Next, on comparing with the industry net income growth, we found that the growth figure reported by Carl Zeiss Meditec compares quite favourably to the industry average, which shows a decline of 2.3% over the last few years. Story Continues XTRA:AFX Past Earnings Growth April 8th 2025 The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. Is AFX fairly valued? This infographic on the company's intrinsic value has everything you need to know. Is Carl Zeiss Meditec Efficiently Re-investing Its Profits? With a three-year median payout ratio of 34% (implying that the company retains 66% of its profits), it seems that Carl Zeiss Meditec is reinvesting efficiently in a way that it sees respectable amount growth in its earnings and pays a dividend that's well covered. Additionally, Carl Zeiss Meditec has paid dividends over a period of at least ten years which means that the company is pretty serious about sharing its profits with shareholders. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 31%. Still, forecasts suggest that Carl Zeiss Meditec's future ROE will rise to 11% even though the the company's payout ratio is not expected to change by much. Conclusion Overall, we feel that Carl Zeiss Meditec certainly does have some positive factors to consider. With a high rate of reinvestment, albeit at a low ROE, the company has managed to see a considerable growth in its earnings. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 27.03.25 08:00:00 | ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach | |
| JENA, Germany, March 27, 2025 /PRNewswire/ -- ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center (International) B.V.) has received National Medical Products Administration (NMPA) approval in China, marking a significant milestone in the product's global journey.ILM-Blue from DORC "ZEISS and DORC are committed to supporting surgeons in the China market with the latest innovation and tools that create a higher standard of care and better patient experience," says Pierre Billardon, Head of Business Sectors Surgery Posterior Segment at ZEISS Medical Technology and CEO of DORC International. "The global success of ILM-Blue underscores the company's commitment to providing high-quality and effective solutions to the ophthalmic community." "We are delighted to bring ILM-Blue to the Chinese market, where it will provide retina surgeons with a proven, high-quality staining solution to enhance visualization," says Jessie Jiang Bo, General Manager of DORC in China. "This approval reinforces our dedication to expanding access to innovative ophthalmic solutions that help surgeons to improve patient outcomes." ILM-Blue® is used to clearly stain and easily distinguish the inner limiting membrane (ILM) from underlying retinal layers during vitreoretinal surgery. This facilitates membrane removal and reduces the risk of retinal damage1. Since its launch in 2010, ILM-Blue® from DORC has been used in more than 900,000 procedures worldwide2, consistently supporting vitreoretinal surgeons to improve patient outcomes and setting new standards in posterior segment surgery. With this latest approval, ILM-Blue® becomes the first DORC posterior dye product available in China, bringing its trusted solution and proven benefits3,4 to healthcare professionals and patients in the region. To date, ILM-Blue® remains the only ILM staining solution approved by the FDA. It is marketed under the brand name TissueBlue® in the U.S. and is listed as the #1 preferred ILM stain among U.S. retina surgeons5. 1 Instructions for use. 2 DORC data on file. 3 Figueroa M.S. et al; Long-term outcomes of 23-gauge pars plana vitrectomy with Internal Limiting Membrane peeling and gas tamponade for myopic traction maculopathy, retina: September 2015 - volume 35 - issue 9 - p 1836-1843 doi: 10.1097/iae.0000000000000554. 4 Veckeneer, M., Mohr, A., Alharthi, E., Azad, R., Bashshur, Z. F., Bertelli, E., ... & Melles, G. R. (2014). Novel 'heavy'dyes for retinal membrane staining during macular surgery: multicenter clinical assessment. Acta Ophthalmologica, 92(4), 339-344. 5 2023 survey of US retinal Surgeons, ASRS meeting, Seattle. Story Continues Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates do not have clinical evidence supporting the opinions and statements of the healthcare professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investors Sebastian Frericks Head of Group Finance & Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220-116 Email: investors.med@zeiss.com Contact for the press Frank Smith Head of Global Communications Ophthalmology Carl Zeiss Meditec Inc. Phone: +49 3641 220 331 Email: press.med@zeiss.com www.zeiss.com/newsroom About Carl Zeiss Meditec AG Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For more information visit our website at www.zeiss.com/med About D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. D.O.R.C. is one of the world's leading suppliers of equipment, instruments and liquids for ophthalmic surgery. For over 40 years, D.O.R.C. has grown into a successful international business, shaping its product portfolio through close collaboration with leading top surgeons. The company improves eye surgery globally and maximizes surgeon control by providing innovative quality approaches for eye disorders. Its products are exported to more than 80 countries worldwide. The company is headquartered in Zuidland, the Netherlands, and has more than 800 employees. In April 2024, D.O.R.C. was acquired by Carl Zeiss Meditec AG.ZEISS SOURCE Carl Zeiss Meditec AG View Comments |
||
| 23.03.25 07:50:56 | Carl Zeiss Meditec AG (ETR:AFX) Stock Goes Ex-Dividend In Just Three Days | |
| Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Carl Zeiss Meditec AG (ETR:AFX) is about to go ex-dividend in just 3 days. The ex-dividend date is two business days before a company's record date in most cases, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is important as the process of settlement involves at least two full business days. So if you miss that date, you would not show up on the company's books on the record date. In other words, investors can purchase Carl Zeiss Meditec's shares before the 27th of March in order to be eligible for the dividend, which will be paid on the 31st of March. The company's next dividend payment will be €0.60 per share, and in the last 12 months, the company paid a total of €0.60 per share. Looking at the last 12 months of distributions, Carl Zeiss Meditec has a trailing yield of approximately 0.9% on its current stock price of €63.95. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. So we need to investigate whether Carl Zeiss Meditec can afford its dividend, and if the dividend could grow. Dividends are typically paid out of company income, so if a company pays out more than it earned, its dividend is usually at a higher risk of being cut. Carl Zeiss Meditec paid out a comfortable 34% of its profit last year. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. The company paid out 103% of its free cash flow over the last year, which we think is outside the ideal range for most businesses. Cash flows are usually much more volatile than earnings, so this could be a temporary effect - but we'd generally want to look more closely here. Carl Zeiss Meditec paid out less in dividends than it reported in profits, but unfortunately it didn't generate enough cash to cover the dividend. Cash is king, as they say, and were Carl Zeiss Meditec to repeatedly pay dividends that aren't well covered by cashflow, we would consider this a warning sign. Check out our latest analysis for Carl Zeiss Meditec Click here to see the company's payout ratio, plus analyst estimates of its future dividends.XTRA:AFX Historic Dividend March 23rd 2025 Have Earnings And Dividends Been Growing? Companies that aren't growing their earnings can still be valuable, but it is even more important to assess the sustainability of the dividend if it looks like the company will struggle to grow. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. That explains why we're not overly excited about Carl Zeiss Meditec's flat earnings over the past five years. We'd take that over an earnings decline any day, but in the long run, the best dividend stocks all grow their earnings per share. Earnings have been growing somewhat, but we're concerned dividend payments consumed most of the company's cash flow over the past year. Story Continues Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. Carl Zeiss Meditec has delivered 4.1% dividend growth per year on average over the past 10 years. The Bottom Line Is Carl Zeiss Meditec an attractive dividend stock, or better left on the shelf? Earnings per share have barely grown in this time, and although Carl Zeiss Meditec is paying out a low percentage of its profit, its dividend was not well covered by free cash flow. It's not common to see a company paying out a limited amount of its profits yet a substantially higher percentage of its cash flow, so we'd flag this as a concern. While it does have some good things going for it, we're a bit ambivalent and it would take more to convince us of Carl Zeiss Meditec's dividend merits. If you want to look further into Carl Zeiss Meditec, it's worth knowing the risks this business faces. Every company has risks, and we've spotted 2 warning signs for Carl Zeiss Meditec you should know about. A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 22.03.25 07:47:51 | Carl Zeiss Meditec's (ETR:AFX) Dividend Will Be Reduced To €0.60 | |
| Carl Zeiss Meditec AG (ETR:AFX) has announced that on 31st of March, it will be paying a dividend of€0.60, which a reduction from last year's comparable dividend. This means that the annual payment is 0.9% of the current stock price, which is lower than what the rest of the industry is paying. While the dividend yield is important for income investors, it is also important to consider any large share price moves, as this will generally outweigh any gains from distributions. Investors will be pleased to see that Carl Zeiss Meditec's stock price has increased by 40% in the last 3 months, which is good for shareholders and can also explain a decrease in the dividend yield. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Carl Zeiss Meditec's Future Dividend Projections Appear Well Covered By Earnings It would be nice for the yield to be higher, but we should also check if higher levels of dividend payment would be sustainable. Before making this announcement, Carl Zeiss Meditec was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business. Over the next year, EPS is forecast to expand by 81.3%. If the dividend continues along recent trends, we estimate the payout ratio will be 20%, which is in the range that makes us comfortable with the sustainability of the dividend.XTRA:AFX Historic Dividend March 22nd 2025 View our latest analysis for Carl Zeiss Meditec Dividend Volatility The company's dividend history has been marked by instability, with at least one cut in the last 10 years. The dividend has gone from an annual total of €0.40 in 2015 to the most recent total annual payment of €0.60. This implies that the company grew its distributions at a yearly rate of about 4.1% over that duration. Modest growth in the dividend is good to see, but we think this is offset by historical cuts to the payments. It is hard to live on a dividend income if the company's earnings are not consistent. The Dividend's Growth Prospects Are Limited With a relatively unstable dividend, it's even more important to evaluate if earnings per share is growing, which could point to a growing dividend in the future. Carl Zeiss Meditec hasn't seen much change in its earnings per share over the last five years. Our Thoughts On Carl Zeiss Meditec's Dividend In summary, dividends being cut isn't ideal, however it can bring the payment into a more sustainable range. The payments haven't been particularly stable and we don't see huge growth potential, but with the dividend well covered by cash flows it could prove to be reliable over the short term. This company is not in the top tier of income providing stocks. Story Continues It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For example, we've picked out 2 warning signs for Carl Zeiss Meditec that investors should know about before committing capital to this stock. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks. Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 21.03.25 14:00:00 | ZEISS Introduces VISULAS Combi in Canada; a Revolutionary Therapeutic Laser Workstation for Enhanced Eye Care | |
| TORONTO, March 21, 2025 /CNW/ -- ZEISS Medical Technology announced today the availability in Canada of the ZEISS VISULAS Combi, an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution. Designed for the treatment of retina, cataract, and glaucoma conditions, the ZEISS VISULAS Combi streamlines workflows with customizable modules, a uniform interface, and space-saving features. It enables seamless eye care without the need for time-consuming changes or relocation of the patient, enhancing both clinical efficiency and the patient experience.ZEISS VISULAS combi Dr. Hady Saheb, a renowned glaucoma expert and President of the Canadian Glaucoma Society, shares, "As an ophthalmologist committed to delivering the best possible care for my patients, I am excited to see the ZEISS VISULAS Combi in practice. I had the opportunity to use the SLT component in conjunction with the ZEISS FORUM and Imaging Solution, and the experience was seamless. The ability to generate treatment reports automatically—without the need to manually enter every detail—is a time-saver for those using the ZEISS FORUM and Imaging Solution. Additionally, the HD Imaging Solution has been invaluable for educating the various learners on the team, eliminating the need for a co-observation tube and allowing multiple learners to watch simultaneously. The SLT laser is performed without bubbles, and the clinical results have also been very promising so far. The ZEISS VISULAS Combi promises to be an exciting new tool for our patients, as the role of SLT laser continues to expand in glaucoma patient care" With Health Canada's approval, ZEISS is pleased to introduce this cutting-edge technology to the Canadian ophthalmology market. Abrar Esop, Head of Medical Technology at ZEISS Canada, explains, "At ZEISS, we are committed to advancing ophthalmic care by improving clinical efficiency and supporting innovation and education. The ZEISS VISULAS Combi embodies our dedication to empowering clinicians and shaping the future of ophthalmology. With its multi-disciplinary capabilities, the ZEISS VISULAS Combi allows ophthalmologists to see more, do more, and treat more—all with one device. Previously, this would have required multiple systems, additional training, and larger workspaces. This platform represents a future-proof investment for ophthalmologists that provides precision and adaptability in one streamlined system." The ZEISS VISULAS Combi sets a new standard in ophthalmic care, offering a versatile and innovative solution that helps simplify the complexities of modern eye care while enabling exceptional outcomes for both patients and practitioners. Discover more: ZEISS VISULAS Combi Story Continues For ophthalmologists based in Canada who would like more information about the ZEISS VISULAS Combi, please contact czcmed@zeiss.com. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. www.zeiss.com/newsroom Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: www.zeiss.com/medZEISS (PRNewsfoto/Carl Zeiss Meditec) SOURCE Carl Zeiss Meditec AGCision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2025/21/c2032.html View Comments |
||
| 17.03.25 05:07:46 | European Market's Hidden Gems: ASML Holding And 2 Other Value Stocks | |
| In the midst of economic uncertainties and fluctuating indices, the European market has been navigating challenges such as U.S. trade tariffs and monetary policy shifts, with major stock indexes showing mixed performances. Despite these hurdles, opportunities arise for discerning investors to identify undervalued stocks that may offer potential value in a volatile environment. Top 10 Undervalued Stocks Based On Cash Flows In Europe Name Current Price Fair Value (Est) Discount (Est) Telefonaktiebolaget LM Ericsson (OM:ERIC B) SEK83.36 SEK164.66 49.4% Fondia Oyj (HLSE:FONDIA) €5.45 €10.63 48.7% JOST Werke (XTRA:JST) €50.00 €98.51 49.2% Storytel (OM:STORY B) SEK92.70 SEK180.62 48.7% dormakaba Holding (SWX:DOKA) CHF680.00 CHF1358.27 49.9% Star7 (BIT:STAR7) €6.20 €12.36 49.8% Cint Group (OM:CINT) SEK6.40 SEK12.79 49.9% Neosperience (BIT:NSP) €0.53 €1.06 49.9% Cavotec (OM:CCC) SEK17.35 SEK34.07 49.1% Fodelia Oyj (HLSE:FODELIA) €7.12 €13.91 48.8% Click here to see the full list of 199 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's uncover some gems from our specialized screener. ASML Holding Overview: ASML Holding N.V. specializes in providing lithography solutions essential for semiconductor equipment systems, with a market capitalization of approximately €257.88 billion. Operations: The company's revenue is primarily generated from its Semiconductor Equipment and Services segment, which accounted for €28.26 billion. Estimated Discount To Fair Value: 15.7% ASML Holding's recent strategic partnership with imec underscores its commitment to innovation and sustainability in the semiconductor industry. The stock trades at approximately €655.7, below its estimated fair value of €778.05, suggesting potential undervaluation based on cash flows. Despite insider selling, ASML is expected to achieve annual earnings growth of 15.4%, surpassing the Dutch market average, while maintaining a high return on equity forecasted at 45.9% over three years. The analysis detailed in our ASML Holding growth report hints at robust future financial performance. Click here and access our complete balance sheet health report to understand the dynamics of ASML Holding.ENXTAM:ASML Discounted Cash Flow as at Mar 2025 Airbus Overview: Airbus SE, along with its subsidiaries, is involved in the design, manufacture, and delivery of aeronautics and aerospace products, services, and solutions globally with a market cap of approximately €133.32 billion. Operations: The company's revenue is primarily generated through its segments: Airbus Helicopters (€7.94 billion), Airbus Defence and Space (€12.08 billion), and Airbus, which includes Holding Function and Bank Activities (€50.65 billion). Story Continues Estimated Discount To Fair Value: 47.1% Airbus is trading at €169.2, significantly below its estimated fair value of €319.77, highlighting potential undervaluation based on cash flows. Earnings have grown 42.2% annually over the past five years and are forecast to grow 17.3% per year, outpacing the French market's average growth rate. Recent regulatory approval in China for value-added telecom services could enhance revenue streams, while ongoing negotiations with Spirit AeroSystems may impact future operations and asset allocations in Belfast. According our earnings growth report, there's an indication that Airbus might be ready to expand. Click to explore a detailed breakdown of our findings in Airbus' balance sheet health report.ENXTPA:AIR Discounted Cash Flow as at Mar 2025 Carl Zeiss Meditec Overview: Carl Zeiss Meditec AG is a medical technology company operating in Germany, the rest of Europe, North America, and Asia with a market cap of approximately €5.61 billion. Operations: The company's revenue is primarily derived from two segments: Ophthalmic Devices, including Surgical Ophthalmology, which contributes approximately €1.61 billion, and Microsurgery, which accounts for about €467.36 million. Estimated Discount To Fair Value: 30.5% Carl Zeiss Meditec is trading at €64.1, significantly below its estimated fair value of €92.21, suggesting undervaluation based on cash flows. Despite a decline in net income to €15.7 million from €37.4 million year-over-year, earnings are expected to grow over 20% annually, surpassing the German market's growth rate of 16.5%. Recent FDA approval for the MEL 90 excimer laser could bolster revenue through expanded offerings in U.S. refractive clinics. Our comprehensive growth report raises the possibility that Carl Zeiss Meditec is poised for substantial financial growth. Dive into the specifics of Carl Zeiss Meditec here with our thorough financial health report.XTRA:AFX Discounted Cash Flow as at Mar 2025 Where To Now? Click through to start exploring the rest of the 196 Undervalued European Stocks Based On Cash Flows now. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Contemplating Other Strategies? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTAM:ASML ENXTPA:AIR and XTRA:AFX. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments |
||
